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The effect of EGF and gefitinib on two EGFR-positive human bladder cancer cell lines has been investigated using array-based gene
expression profiling. The most prominent transcript, increased up to 6.7-fold by EGF compared with controls in RT112 cells, was
human early growth response protein 1 (hEGR1). This induction was prevented by gefitinib. The hEGR1 mRNA in EGF-treated
samples was reduced in the presence of gefitinib, as was hEGR1 protein in cell lysates. In the RT4 cells, hEGR1 expression was halved
in the presence of EGF and gefitinib in combination. In bladder tumour samples, there was a significant correlation between hEGR1
mRNA detected by RT-PCR and EGFR detected by ligand binding, (P¼0.042). The induction by EGF of the hEGR1 gene, mRNA and
protein in RT112 cells, and its inhibition by gefitinib, together with the detection of hEGR1 mRNA in bladder tumours, suggests that
hEGR1 may be important in the EGFR growth-signalling pathway in bladder cancer and should be further investigated for its
prognostic significance and as a potential therapeutic target.
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Growth factors and their receptors are important in tumour
development and progression. Several studies have shown that the
presence of epidermal growth factor receptor (EGFR) in bladder
cancer is associated with high tumour stage and grade and is a
strong independent predictor of tumour stage progression and
poor long-term survival (Neal et al, 1985, 1990; Lipponen and
Eskelinen, 1994; Mellon et al, 1995). Bladder cancer is the fifth
most common cancer in men, with an annual incidence of 24.7
per 100000 population in the UK. 90% of bladder tumours are
transitional cell carcinoma (TCC) and can be broadly divided into
superficial (Ta and T1) or muscle invasive (T2, T3 and T4) forms.
Approximately 50–70% of superficial tumours recur, following
removal at cystoscopy, of which 10–20% will become invasive. At
present there is no reliable method to predict which superficial
tumours will show invasive progression or metastasize.
EGFR is a member of the erbB family of cell surface receptors,
which comprises four homologous receptors: EGFR (erbB-1/
HER1); erbB-2 (HER2/neu); erbB-3 (HER3) and erbB-4 (HER4).
These receptors are composed of an extracellular ligand-binding
domain, a transmembrane domain and an intracellular protein
kinase domain. Ligand binding activates the EGFR by inducing
homo- or hetero-dimerisation with other members of the erbB
family, resulting in autophosphorylation of both intracellular
tyrosine kinase domains. This initiates a cascade of intracellular
signalling events that promote growth and the expression of genes
involved in malignant progression (Olayioye et al, 2000).
EGFR signalling is critical not only for cell proliferation but also
in other processes crucial to cancer progression, and EGFR has
therefore been explored as a target for anticancer therapies. One
approach for the therapeutic blockade of EGFR signalling has been
the discovery and development of low molecular weight com-
pounds that inhibit the ligand-binding induced activation of the
EGFR tyrosine kinase. Gefitinib (‘Iressa’, ZD1839) is an orally
active EGFR tyrosine kinase inhibitor (EGFR-TKI). It is a low
molecular weight synthetic quinazoline derivative that has
been shown to block signal transduction pathways implicated in
the proliferation and survival of cancer cells and other host-
dependent processes promoting cancer cell growth (Wakeling
et al, 1996; Woodburn, 1999). Gefitinib and other EGFR inhibitors,
and results of clinical trials using gefitinib in cancer patients, have
recently been reviewed (Blackledge and Averbuch, 2004; Herbst
et al, 2004).
This study investigates the effect of the tyrosine kinase inhibitor
gefitinib and EGF on the gene expression patterns of two human
bladder tumour cell lines, and the subsequent investigation of
human early growth response protein 1 (hEGR1) found to be
prominently induced by EGF but not in the presence of gefitinib.
The relationship between hEGR1 and EGFR in human bladder
tumours was also investigated.
METHODS
Cell culture
Two human bladder tumour cell lines, RT4 and RT112, were
obtained from ECACC (Porton Down, UK) and routinely grown in
RPMI 1640 medium containing L-glutamine, 1mM pyruvate and
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s10% foetal bovine serum (FBS). All cells were negative for
mycoplasma. Both cell lines expressed EGFR (Nutt et al, 2004)
and cells were treated as described previously (Nutt et al, 1998).
Briefly, cells at 50% confluence were depleted of serum for 24h
to remove exogenous growth factors and treated with 10ngml
 1
EGF (Sigma-Aldrich) and/or 1mM gefitinib in serum-free medium
continuously for 48h. Gefitinib (1mM) had previously been shown
not to inhibit cell growth (Nutt et al, 2004). Following incubation,
the cells were washed twice with ice-cold PBS, scraped from the
culture dishes, centrifuged and the cell pellets stored at  801C
prior to extraction of RNA. For Northern analysis, cells were
treated with 10 or 50ngml
 1 EGF for up to 48h and processed as
above. Control cells were grown in exactly the same way in serum-
free medium.
Array analysis
RNA was extracted using Qiagen RNeasy Midi kit, the lysis buffer
being added directly to the frozen cell pellets, which were then
homogenised by 10–15 passes through a 20 gauge needle. RNA
samples were treated with DNase (Ambion DNA free kit) and the
RNA quality was assessed using 1.2% agarose gel electrophoresis
with ethidium bromide staining. RNA concentrations were
measured using absorbance at 260nm.
Gene expression analysis was performed using Clontech Atlas
Human Cancer 1.2 Arrays (BD Biosciences, Cowley, Oxford, UK).
cDNA labelled with
32P was synthesised from the samples of total
RNA using the Clontech Pure Total RNA labelling kit (the RNA is
immobilised onto streptavidin-coated magnetic beads with biotiny-
lated oligo(dT) and allows both poly A
þ RNA enrichment and probe
synthesis in a single procedure). The RNA was reverse transcribed
with a specific primer mix for the genes on the array. The cDNA
mixture was then separated from unincorporated labelled nucleotides
using nucleospin extraction columns supplied in the kit. The filters
were prehybridised at 681C with denatured salmon testes DNA, and
hybridised with Cot-1 DNA (GibcoBRL, Life Technologies, Invitrogen
Ltd, Paisley, UK) as blocking agents on the filters. Hybridisation was
performed overnight at 681C. The array filters were washed six times
in 2  SSC/1%SDS buffer, prior to exposure to a Molecular Dynamics
Phosphor screen for 1–5 days at 41C.
Signals were analysed using Molecular Dynamics ImageQuant
v5.0 and Clontech AtlasImage Analysis v1.5 and normalised using
the sum of global intensities. The intensity difference and
expression ratio were calculated for each gene. The expression
ratio was defined as the intensity of the gene signal in the treated
sample compared with the serum-free control.
After analysis, the array membranes were stripped by boiling in
0.5% SDS for 5min. Repeat hybridisations were performed with
freshly prepared probes and cross over of samples. Membranes
were reprobed a maximum of three times.
PCR analysis
To confirm the hEGR1 gene expression and its modulation by EGF
and gefitinib in the cell lines, RT-PCR was performed using the
Invitrogen Superscript First strand synthesis system with random
primers. The human EGR1 specific primers used were: SN
CTGCACGCTTCTCAGTGTTC and ASN AGCAGCATCATCTCCTC
CAG (Chen et al, 2001). PCR was performed for 36 cycles: 941C
30s; 551C3 0s ;7 2 1C 30s; then 41C. PCR products were analysed by
electrophoresis on a 2% NuSieve 3:1 (Flowgen Bioscience Ltd,
Nottingham, UK) agarose gel and detected by fluorescence staining
with ethidium bromide.
Western blot analysis
Western blotting was performed to determine the effects of EGF on
expression of the hEGR1 protein. Cell lysates were prepared and
60mg aliquots of protein from each sample were loaded on a
4–20% gradient polyacrylamide gel. Following SDS-PAGE and
electroblotting (Towbin et al, 1979), membranes were blocked
using a 5% milk solution prior to incubation with an hEGR1 rabbit
polyclonal antibody (Santa Cruz, sc-110) at a final concentration of
1mgml
 1 followed by a secondary HRP-conjugated antibody
(Goat-antirabbit, Dako UK Ltd, Ely, Cambridgeshire, UK). Anti-
body labelled protein bands were visualised by enhanced
chemiluminescent detection (ECL) (Amersham Biosciences, GE
Healthcare UK Ltd, Little Chalfont, Bucks, UK). Equal loading of
protein was verified using anti-actin antibody (Sigma-Aldrich Co
Ltd, Poole, UK).
RNA extraction and Northern blot analysis
Total RNA was extracted from the frozen cell pellets using the
phenol-guanidinium isothiocyanate method (Chomczynski and
Sacchi, 1987) with the commercial reagent RNAzol (Biogenesis,
Poole, UK). The RNA pellet was dissolved in water, the
concentration determined by absorbance at 260nm and the
samples stored at  701C.
Northern blot analysis was performed using the glyoxal method
as previously described (Nutt et al, 1991). Briefly, 20mg samples of
RNA were treated by glyoxylation prior to electrophoresis on 1.2%
agarose gel in 10mM phosphate buffer. The gel was stained with
ethidium bromide to verify equal loading of samples before
capillary transfer of the RNA overnight onto Hybond-N nylon
membrane (Amersham Biosciences, Little Chalfont, UK). After
transfer and air drying, RNA was fixed to the membrane by ultra
violet irradiation cross-linking for 3.5min using a mid range
transilluminator (UltraViolet products Inc., UK).
Radioactive probes, from cDNA prepared by RT-PCR, were
prepared by the random primer extension method using a
32P-ATP
(Amersham, UK). Primers for hEGR1 probe preparation were
designed to give a product of approximately 1kb: SN 50-
CTTCAACCCTCAGGCGGACACG-30; ASN 50-CGGGGACGGGTAA
GAGGTAGCA-30. RNA samples were used for RT-PCR, using the
Invitrogen Superscript First strand synthesis system. PCR products
were electrophoresed in a 1% agarose gel and the product detected
and yield estimated by ethidium bromide staining. The product
band was extracted using a QIAquick gel extraction kit (Qiagen,
UK). DNA (50ng) aliquots were used directly in the random
primer extension radioactive labelling reaction.
After deglyoxylation by boiling in water for 5min, the filters
were prehybridised at 651C for 3h in hybridisation solution (0.5 M
sodium phosphate buffer, pH 7.0; 1mM EDTA; 1% BSA; 7% SDS)
with 1mgml
 1 denatured salmon sperm DNA, to block non-
specific DNA binding sites. Hybridisation was carried out over-
night using 10
6cpm of probeml
 1 hybridisation solution. The
filters were then washed twice in 2  SSC, 0.2% SDS at 651C for
5min and a final wash for 15min at 651C. To detect the bound
radioactivity the filters were exposed to a PhosphorImager screen
(Molecular Dynamics, UK).
PCR analysis of bladder tumours
RNA prepared from human bladder tumours was reverse
transcribed as previously described. PCR was performed for both
hEGR1 and actin. The primers used for actin were SN 50-CAA CTC
CAT GAA GTG TGA-30 and ASN 50-GCC ATG CCA ATC TCA TCT
TG-30 to give a product size of 377bp. The primers for hEGR1 and
actin were used in the ratio 4:1. PCR was performed by heating to
941C for 10min, then 40 cycles of 941C3 0s ,5 5 1C3 0s ,7 2 1C 1min,
followed by 721C 7min, then 41C.
PCR products were run on an agarose gel and bands stained
with ethidium bromide were quantified using a Biorad Imager.
Samples from RT112 and RT4 cells treated with 10ngml
 1 EGF for
up to 4h were also used, and the RT112 sample treated for 1h was
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sused as a positive control in all runs. The ratio of hEGR/actin from
densitometry was compared with the tumour EGFR level obtained
by ligand binding assay as previously reported for this panel of
tumours, with EGFR positive tumours defined by EGF binding of
410fmolmg
 1 protein (Mellon et al, 1996).
RESULTS
Array analysis
The Qiagen kit yielded high quality, pure RNA and agarose gel
electrophoresis consistently showed no degradation of the RNA.
The array analysis produced well-defined expression profiles with
low background intensity.
In the RT112 cell line, the most prominent increase in
expression was that of the hEGR1 gene which was induced in
multiple hybridisations when the cells were stimulated with
10ngml
 1 EGF. In four hybridisations from two cell culture
experiments, hEGR1 was clearly visible above background on
control arrays. hEGR1 was induced by EGF, with expression ratios
ranging from 2.3 to 6.7 and a mean expression ratio of 4.7 was
obtained from three experiments. A comparison of hybridisation
to the array between cDNA probes made from control and EGF
treated cells showing differential expression of hEGR1 in RT112
cells treated with EGF is shown in Figure 1. This illustrates an
example of the reproducibility observed. The expression of hEGR1
was suppressed with 1mM gefitinib, giving an expression ratio of
0.5 when the treated samples were compared with controls. When
both 10ngml
 1 EGF and 1mM gefitinib were incubated together
with the cells, an expression ratio of 0.56 was obtained.
With the RT4 cell line, hEGR1 was again induced when the cells
were incubated with EGF and with gefitinib. Although the intensity of
hEGR1 was increased the expression ratio was undefined, since a
ratio requires above background gene expression in membranes used
with both control and treated samples. However, EGF and gefitinib
used in combination was observed to suppress the hEGR1 seen as
above background in the untreated control sample. The expression
ratio with the combined treatment ranged from 0.26 to 0.5.
Some of the other genes affected by EGF treatment are listed in
Table 1 (RT112 cells) and Table 2 (RT4 cells). Genes with the
highest ratio for upregulation and the lowest ratio for down
regulation with EGF treatment are included. hEGR1 was the only
Figure 1 AtlasImage comparison between array hybridisations showing differential expression of hEGR1 in EGF-treated RT112 cells. The intensity is
calculated for cells treated with 10ngml
 1 EGF (right) and the serum free controls (left) and the ratio between treated and untreated controls is calculated
from the adjusted intensities for each gene.
Table 1 Gene transcript levels altered by EGF in RT112 cells and effects
of gefitinib treatment with and without EGF
Gene EGF Gefitinib EGF+gefitinib
Cytosolic superoxide dismutase 1 6.9 6.6 4.8
Vitronectin precursor 5.3 ND ND
Early growth response protein 1 4.7 0.5 0.56
Interferon g-induced protein precursor 4.7 2.5 ND
c-jun 4.0 3.4 3.9
Tissue inhibitor of metalloproteinase 3 4.0 ND 2.4
Cytohesin-1 0.2 ND ND
Tissue inhibibitor of metalloproteinase 1 0.2 0.45 0.3
GTP-binding protein 0.3 ND ND
Alpha 1 catenin 0.3 0.4 ND
Cytokeratin 8 0.3 ND ND
BRCA1 associated ring domain protein 0.35 0.4 0.35
Numbers indicate the ratio of expression in treated cells relative to untreated
controls. Bold indicates upregulation of the gene compared to control treatment. ND
indicates there is no difference relative to the untreated control.
Table 2 Gene transcript levels altered by EGF in RT4 cells and effects of
gefitinib treatment with and without EGF
Gene EGF Gefitinib EGF+Gefitinib
Integrin b4 4.1 ND 0.2
Early growth response protein 1 Un 43U n 43 0.38
P16-INK4 3.0 4 0.2
Macrophage inhibitory cytokine1 3.0 ND 1.2
Interferon-induced protein P78 3.0 ND ND
c-jun 2.6 ND ND
Tissue inhibitor of metalloproteinase 3 2.6 ND ND
Semaphorin 0.2 0.3 ND
Cytokeratin 18 0.2 0.3 0.1
Tissue inhibitor of metalloproteinase 1 0.4 0.5 0.35
Fatty acid synthase 0.4 ND ND
Lactate dehydrogenase H subunit 0.4 ND 2.2
Numbers indicate the ratio of expression in treated cells relative to untreated
controls. Bold indicates upregulation of the gene compared to control treatment. ND
indicates there is no difference relative to the untreated control. Un indicates the
ratio was undefined because the untreated control levels were below background.
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sgene where differential expression was observed between EGF and
combined EGF/gefitinib treatment in both cell lines.
RT-PCR validation of hEGR1 induction
RNA samples from RT112 cells were used for RT-PCR using
primers for hEGR1 designed to give a product of 253 base pairs
(see Methods). The results are shown in Figure 2, with EGF
showing a large increase in the hEGR1 RT-PCR product compared
to the control. Very little product was present with gefitinib alone,
and the product with EGF and gefitinib in combination was
reduced compared with EGF alone, confirming the inhibitory effect
of gefitinib on the induction of hEGR1 transcripts by EGF.
Northern analysis
The time course of hEGR1 mRNA induction following EGF
treatment of RT112 cells was investigated by Northern blot
analysis (Figure 3A and B). A single 3.1Kb transcript was detected.
hEGR1 transcript levels increased rapidly within 30min of EGF
treatment, with both 10 and 50ngml
 1 EGF, and reached a
maximum at 1h. After 2h continuous treatment, transcript levels
had fallen, and by 4h there was no evidence of any hEGR1
induction (Figure 3A). Later time points at both 24 and 48h
showed induction with EGF, with no evidence of induction of
hEGR1 in controls without EGF grown in serum-free medium for
the same length of time (Figure 3B).
Incubation of RT112 cells for 48h with 1mM gefitinib alone
showed no hEGR1 induction. The increase in levels of hEGR1
mRNA seen with EGF treatment was prevented by the presence of
gefitinib (Figure 3C). Equiloading was demonstrated by the 28S
RNA band. These results demonstrate that hEGR1 is induced as an
early growth response protein, but is also elevated at later time
points and that the induction by EGF is inhibited by the EGFR
tyrosine kinase inhibitor.
In the RT4 cells, induction of hEGR1 was again seen when cells
were treated with EGF for 48h (Figure 3C) in agreement with the
results from the array analysis.
Western analysis
Western Analysis for hEGR1 protein in the RT112 and RT4 cell
lysates treated with EGF with or without gefitinib for 48h, detected
very low levels of hEGR1 protein following treatment only with
EGF alone and not in the presence of gefitinib (Figure 4A).
Subsequently, hEGR1 protein was detected at 80kDa following
EGF stimulation with 10ngml
 1 at 5 and 50h in the RT112 cell
lysate (Figure 4B). The gels were also probed for b-actin, shown in
the lower panel of each part of the figure.
PCR analysis of bladder tumours
By using RT-PCR, hEGR1 was shown to be induced in both RT112
and RT4 cells following stimulation with EGF after 1h. The
induction was reduced to control levels after 4h of treatment
(Figure 5A). The RT112-treated samples were used as a positive
control in subsequent analyses of bladder tumour samples and
using densitometry gave a mean ratio of hEGR/actin of 0.54
(s.d.70.11, n¼3). A selection of the bladder tumour samples
analysed is shown in Figure 5B. The ratio of hEGR/actin ranged
from 0.113 to 0.437. The results from triplicate experiments for 14
bladder tumour samples of known and previously reported EGFR
status approached significance at the 95% confidence level
(P¼0.054, Mann–Whitney test), with a trend towards higher
hEGR/actin ratios in EGFR positive tumours. A tumour was
defined as EGFR positive if the ligand binding was 410fmolmg
 1
protein and showed positive staining for EGFR by immunohisto-
Control 0 h
Control 48 h
EGF 10 ng ml
–1  48 h
Gefitinib 1 M 48 h
EGF 10 ng ml
–1
+Gefitinib 1 M 48 h
DNA ladder
369 bp
246 bp hEGR1
Figure 2 RT112 cell RT-PCR products detected with ethidium bromide
following electrophoresis in a 2% agarose gel. Treatment of cells was for
48h as indicated.
Control
EGF 10 ng ml –1
Gefitinib 1 M
EGF 10 ng ml
–1
+Gefitinib 1 M
Control
EGF 10 ng ml
–1
Gefitinib 1 M
EGF 10 ng ml
–1
+Gefitinib 1 M
EGR1 3.1 kb
28S RNA 4.8 kb
Time (h)
EGF (ng ml–1)
0 0.5 0.5 1 1 2 2 4 4
— 10 50 10 50 10 50 10 50
Time (h)
EGF (ng ml
–1)
24 02 4 2 4 4 8 4 8 4 8
— 50 10 — 50 10 —
A
B
C
EGR1 3.1 kb 
EGR1 3.1 kb 
RT4 RT112
Figure 3 Northern blot analysis of RNA using a radioactive probe for
hEGR1.( A) Early induction of hEGR1 following EGF stimulation in RT112
cells; (B) sustained hEGR1 induction following EGF stimulation for 24 and
48h in RT112 cells; (C) induction of hEGR1 by EGF at 48h and inhibition of
this induction with gefitinib in RT112 (left panel) and RT4 cells (right panel).
28S RNA bands indicate equal loading of RNA.
EGR1
Actin
Control
0.5 h
1.5 h
5.0 h
16 h
50 h
96 kDa
EGR1
Actin
Control
EGF 10 ng ml
–1
Gefitinib 1 M
Gefitinib 5 M
Gefitinib 1 M+EGF
Gefitinib 5 M+EGF
A
B
Figure 4 Western blot analysis for hEGR1 and actin in RT112 cell lysates
following treatment of cells: (A) with EGF, gefitinib or a combination for
48h; (B) with EGF for up to 50h.
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schemistry. The mean values (7s.e.m.) of the EGFR positive
samples and EGFR negative samples were 0.252 (70.036) and
0.165 (70.020) respectively. There was, however, a significant
correlation between the EGFR measurements from ligand binding
assays and the hEGR/actin ratio (P¼0.042, r
2¼0.302) as shown in
Figure 6. There was no statistical difference in hEGR/Actin ratio in
relation to stage or grade of tumours (data not shown).
DISCUSSION
Intracellular signalling from the EGF receptor is known to follow
two pathways, the activated ras and mitogen-activated protein
(MAP) kinase cascade or the JAK-STAT (janus kinase/signal
transducers and activators of transcription) complex (Leaman
et al, 1996). The involvement of hEGR1 in the EGFR stimulation of
bladder tumour cells adds further detail to the downstream effects
of intracellular signalling from EGFR in bladder tumours. Several
immediate early response genes are transiently activated in serum
or growth factor stimulated cells in culture and include the early
growth response protein-1 (hEGR1)/nerve growth factor-induced
protein A (NGFI-A). EGR1 is a nuclear zinc-finger transcription
factor belonging to the EGR family, which includes WT1.
Extracellular stimuli that induce EGR1 can be grouped into
mitogens, developmental and differentiation processes, tissue or
radiation injury and signals that cause neuronal excitation
(Gashler and Sukhatme, 1995). EGR1 can act as a positive or
negative regulator of gene expression, depending on cell type,
although its precise function in growth regulation remains unclear.
There have been few reported studies of hEGR1 in bladder
cancer but the role of hEGR1 in prostate tumours has recently been
reviewed (Adamson et al, 2003). hEGR1 expression has been
reported to correlate with increased growth and malignancy in
prostate cancer, and to be involved in the maintenance of prostate
tumour cell proliferation (Thigpen et al, 1996; Eid et al, 1998). In
the latter study, progression of tumours directly required EGR1,
and was halted in studies involving EGR1 /  knockouts. Using
gene microarrays, expression of hEGR1 target genes in prostate
carcinoma cells were identified and include growth factors such as
IGFII, PDGF-A and TGF-b1 which have been implicated in
enhancing tumour progression (Svaren et al, 2000). Increased
levels of hEGR1 mRNA were demonstrated in poorly differentiated
malignant prostate tissues and those with more aggressive
pathology (Eid et al, 1998). As RT112 cells were derived from a
moderately differentiated tumour and RT4 cells from a well
differentiated tumour (Masters et al, 1986), this could explain the
larger hEGR1 induction in the RT112 cell line. The RT112 cells are
also more invasive than the RT4 cells (Booth et al, 1997), and
hence more aggressive, which may also affect the hEGR1 induction.
Most reports on EGR1 demonstrate the gene product to be
rapidly and transiently expressed and EGR1 is generally seen as an
early response gene (with increased levels usually within an hour
of cellular stimulation). Our results demonstrate not only an early
(1–2h) transient response to EGF, but also a subsequent
prolonged response at both 24 and 48h in RT112 cells. This
response is seen at both the mRNA and protein level, and is
inhibited by the EGFR tyrosine kinase inhibitor gefitinib. It is
possible that most previous investigations of EGR1 induction have
only been studied over a short time scale, as the name would
suggest. Also, since hEGR1 is induced during the G0 to G1
transition (Molnar et al, 1994) and the doubling time for the RT112
cells is approximately 24h (Masters et al, 1986) this may explain
the induction of hEGR1 at the later time points. It could also be
due to the auto-induction of EGFR (Saadane et al, 2000). EGFR
expression was upregulated after induction of hEGR1 during
hypoxic exposure of human tumour cells (U-2OS) (Nishi et al,
2002) and it was found that hEGR1 directly induced EGFR
transcription. This positive autoregulatory feedback loop that
restores EGFR protein levels to enable tumour growth in hypoxic
conditions may also occur in other conditions. A study of the
expression of hEGR1 in late stage emphysema (Zhang et al, 2000)
demonstrates that lung tissue from these patients compared with
control samples displays a selective and apparently sustained
increase in hEGR1 transcripts and proteins compared with a broad
survey of other genes, including the transcription factor SP1 which
was not significantly altered. The sustained hEGR1 induction
described leads to the question as to whether hEGR1 and hEGR1-
regulated genes contribute to the pathogenesis or progression of
late stage emphysema. It is interesting that, when induced, hEGR1
often displaces other zinc finger transcription factors such as SP1
from the GC-rich binding sites where the transcription factors
support basal expression of genes such as tissue factor (TF)
resulting in maximal transcriptional activation of the target genes
(Cui et al, 1996).
The expression of hEGR1 in normal or malignant tissues varies,
depending on the tissue. hEGR1 expression was reported not to
be significantly higher in bladder cancer than normal tissue
(Ogishima et al, 2005) and no significant relationship was observed
between hEGR1 expression and pathological findings. Our results
demonstrate a significant correlation between the number of EGF
receptors and the expression of hEGR1 in bladder tumours,
although no difference in hEGR1 expression was detected with
stage or grade of tumour. Increased levels of hEGR1 have been
demonstrated in prostate cancer compared with benign prostate
tissue, with hEGR1 located predominantly in the cytoplasm in
malignant cells (Mora et al, 2004). In breast cancer cell lines and
tumours, reduced hEGR1 expression compared with normal
246 bp
369 bp Actin
EGR1
EGR1
Actin 369 bp
A
B
246 bp
bp ladder
RT112 EGF 1 h
RT112 EGF 2 h
RT4 control
RT4 EGF 1 h
RT4 EGF 4 h
RT112 EGF 4 h
bp ladder
Bladder tumour samples
Figure 5 Agarose gel electrophoresis of RT-PCR products of hEGR1 and
actin (A) from RT112 and RT4 cells treated with EGF; (B) from a selection
of bladder tumour samples.
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Figure 6 Relationship between hEGR/Actin ratio and EGFR (fmolmg
 1
protein) measured by ligand binding.
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smammary cell lines and tissues has been reported (Huang et al,
1997). The authors suggested that hEGR1 may act like a tumour
suppressor gene of the Type II class where expression is down
regulated in tumours. hEGR1 could therefore be a target for
therapy by reactivating its expression in this situation. Little or no
hEGR1 expression was found in human small cell lung tumours
compared with adjacent normal tissues (Levin et al, 1995). From
studies using EGR1-null mouse embryo fibroblasts it was proposed
that EGR1 is a major regulator of cell senescence and an upstream
‘gatekeeper’ of the p53 tumour suppressor pathway (Krones-
Herzig et al, 2003).
A study on human gliomas (Calogero et al, 2001) also suggests
that hEGR1 may function as a tumour suppressor. hEGR1 was
found to be suppressed at both mRNA and protein levels in
gliomas and hEGR1 itself is implicated as a target of suppression
during tumour progression. Studies on glioma cells (Kaufmann
and Thiel, 2001) following EGF stimulation indicated that hEGR1
may be an important part of the EGF-initiated signalling cascades
and showed that hEGR1 gene transcripts and protein were
undetectable in the absence of cell stimulation by EGF. A similar
proposal that hEGR1 may be an important late part of the EGF
signalling cascade is reported in a study of EGF and thrombin on
keratinocytes (Kaufmann and Thiel, 2002). EGF induced a
transient synthesis of hEGR1 with a peak between 1 and 5h.
Proliferation, activation of ERK and biosynthesis of hEGR1 was
inhibited by AG1487, an EGFR specific tyrosine kinase inhibitor.
Another tyrosine kinase inhibitor, erlotinib, has been shown to
inhibit a potent radiation-induced enhancement of hEGR1 in a
head and neck SCC cell line (UM-SCC6) using a 24h pre-
incubation with erlotinib (Chinnaiyan et al, 2005). Our results
demonstrate the inhibition of hEGR1 induction in bladder tumour
cell lines with the EGFR tyrosine kinase inhibitor gefitinib.
Other genes found to be affected by EGF and gefitinib have not
been further investigated since hEGR1 was the only gene which was
upregulated with EGF and downregulated with a combination of
EGF and gefitinib treatment in both cell lines. It is, however,
interesting that EGF produced opposite effects on tissue inhibitor
of metalloproteinase (TIMP) 3 and TIMP1 in both cell lines and
only a few genes were seen to be affected in the same way in the
two cell lines studied (upregulation of c-jun and TIMP3; down-
regulation of TIMP1).
The sustained induction of hEGR1 by EGF in the RT112 bladder
tumour cells for 24 and 48h, in addition to the rapid induction
seen at 1 to 2h, indicates that further investigation of the role of
hEGR1 and EGFR in bladder tumours is warranted. The presence
of hEGR1 in tumours is shown here to be related to EGFR status
and may be an important causal link to the growth and
progression of bladder tumours. The detection of hEGR1 mRNA
in varying quantities in all tumour samples used in this study and
the significant correlation between hEGR1 and EGFR are an
indication of its importance in bladder cancer. To date there are no
reports as to whether there are any somatic mutations in EGFR in
bladder cancer cell lines which may affect the responsiveness to
gefitinib (Lynch et al, 2004). The absence of hEGR1 mRNA in the
bladder tumour cells without EGF stimulation also indicates that
hEGR1 is not constitutively expressed. Further investigation of the
intracellular signalling pathways involved in the hEGR1 induction
by EGF and its inhibition by gefitinib would clarify the role of
hEGR1 in EGFR-dependent tumour growth and progression and its
inhibition by gefitinib.
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